The global ctDNA Detection Kit market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of % from 2025 to 2031.
Circulating tumor DNA (ctDNA) detection, the so-called "liquid biopsy". ctDNA refers to DNA released by tumor cells into the blood circulation system, which contains tumor-derived mutation and genetic variation information. ctDNA is a tumor marker with broad application prospects, high sensitivity and specificity, and is suitable for a variety of tumors, providing opportunities for non-invasive tumor sampling.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years.
Key Features:
- Comprehensive analysis by region and market sector.
- Detailed analysis of world ctDNA Detection Kit industry.
- Insights on product segmentation, company formation, revenue, and market share.
Segmentation by Type:
- Quantitative Testing
- Qualitative Testing
Segmentation by Application:
- Hospital
- Clinic
- Other
Market by Region:
- Americas
- APAC
- Europe
- Middle East & Africa
Company Coverage:
- Grail, Inc.
- Guardant Health, Inc.
- Biodesix, Inc.
- Exosome Diagnostics
- Freenome Inc.
- LungLife AI, Inc.
- Inivata Ltd.
- Personal Genome Diagnostics, Inc.
- CellMax Life
- Nonacus
Key Questions Addressed in this Report:
- What is the 10-year outlook for the global ctDNA Detection Kit market?
- What factors are driving ctDNA Detection Kit market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do ctDNA Detection Kit market opportunities vary by end market size?
- How does ctDNA Detection Kit break out by Type, by Application?
Frequently Asked Questions
What is the USP of the report? expand_more
What are the key content of the report? expand_more
- Global Market Players
- Geopolitical regions
- Consumer Insights
- Technological advancement
- Historic and Future Analysis of the Market